AR101227A1 - COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN - Google Patents
COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAINInfo
- Publication number
- AR101227A1 AR101227A1 ARP150102272A ARP150102272A AR101227A1 AR 101227 A1 AR101227 A1 AR 101227A1 AR P150102272 A ARP150102272 A AR P150102272A AR P150102272 A ARP150102272 A AR P150102272A AR 101227 A1 AR101227 A1 AR 101227A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- phenoxibencenosulfonamide
- tiazolil
- gabapentine
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002870 gabapentin Drugs 0.000 title abstract 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método de tratar dolor que comprende la administración separada, secuencial o simultánea a un individuo en necesidad de dicho tratamiento de una cantidad terapéuticamente efectiva de un compuesto de conformidad con la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde -Y es -Cl o -CF₃; y de una cantidad terapéuticamente efectiva de gabapentina o pregabalina, o una sal farmacéuticamente aceptable del mismo. Reivindicación 11: Una forma de dosificación farmacéutica, caracterizada porque comprende un compuesto de conformidad con la fórmula (1) y un segundo compuesto farmacéuticamente activo, como se define en cualquiera de las reivindicaciones 1 a 6, o una sal farmacéuticamente aceptable de uno o ambos dichos compuestos, y uno o más excipientes farmacéuticamente aceptables. Reivindicación 16: El uso de un compuesto de conformidad con la fórmula (1) como se define en la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, caracterizado porque es para la fabricación de un medicamento para el tratamiento de dolor, en donde el tratamiento comprende además la administración separada, secuencial o simultánea de un segundo compuesto como se define en la reivindicación 1, o una sal farmacéuticamente aceptable del mismo.A method of treating pain comprising the separate, sequential or simultaneous administration to an individual in need of said treatment of a therapeutically effective amount of a compound according to formula (1) or a pharmaceutically acceptable salt thereof, wherein -Y is -Cl or -CF₃; and of a therapeutically effective amount of gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof. Claim 11: A pharmaceutical dosage form, characterized in that it comprises a compound according to formula (1) and a second pharmaceutically active compound, as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt of one or both said compounds, and one or more pharmaceutically acceptable excipients. Claim 16: The use of a compound according to formula (1) as defined in claim 1, or a pharmaceutically acceptable salt thereof, characterized in that it is for the manufacture of a medicament for the treatment of pain, wherein the Treatment further comprises separate, sequential or simultaneous administration of a second compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025553P | 2014-07-17 | 2014-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101227A1 true AR101227A1 (en) | 2016-11-30 |
Family
ID=53969384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102272A AR101227A1 (en) | 2014-07-17 | 2015-07-16 | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2016029033A (en) |
| AR (1) | AR101227A1 (en) |
| CA (1) | CA2897306A1 (en) |
| TW (1) | TW201605439A (en) |
| WO (1) | WO2016009303A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180096683A (en) | 2015-12-18 | 2018-08-29 | 머크 샤프 앤드 돔 코포레이션 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN114073698B (en) | 2020-08-20 | 2023-03-31 | 山西泰睿鑫科技有限公司 | Pain-relieving and itching-relieving pharmaceutical composition and application method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| DE602008000809D1 (en) | 2007-03-23 | 2010-04-29 | Icagen Inc | Ion channel inhibitors |
| PE20142099A1 (en) | 2009-01-12 | 2014-12-13 | Icagen Inc | SULFONAMIDE DERIVATIVES |
| CA2861439C (en) | 2012-02-03 | 2016-07-12 | Pfizer Inc. | Benzimidazole and imidazopyridine derivatives as sodium channel modulators |
-
2015
- 2015-07-06 WO PCT/IB2015/055100 patent/WO2016009303A1/en active Application Filing
- 2015-07-14 CA CA2897306A patent/CA2897306A1/en not_active Abandoned
- 2015-07-15 JP JP2015140980A patent/JP2016029033A/en active Pending
- 2015-07-16 TW TW104123119A patent/TW201605439A/en unknown
- 2015-07-16 AR ARP150102272A patent/AR101227A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2897306A1 (en) | 2016-01-17 |
| JP2016029033A (en) | 2016-03-03 |
| TW201605439A (en) | 2016-02-16 |
| WO2016009303A1 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (en) | Treatment methods for cystic fibrosis. | |
| CL2019003091A1 (en) | Combination therapy. | |
| AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
| EA201590166A8 (en) | COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS | |
| CR20180253A (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| CL2019002172A1 (en) | Therapeutic agent for liver diseases. | |
| EA201501164A1 (en) | SOLID PHARMACEUTICAL MEDICINE FORM | |
| CO2019004004A2 (en) | Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease | |
| AR103118A1 (en) | ANAMORELINE-BASED MEDICAL TREATMENTS | |
| AR101901A1 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES WITH A COMBINATION OF LAQUINIMOD AND FINGOLIMOD | |
| CL2019003463A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e) -4- (2- (aminomethyl) -3-fluoroallyloxy) -n-tert-butylbenzamide, process for its preparation, methods for treatment and uses thereof. | |
| AR099299A1 (en) | INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| EA201390345A1 (en) | THERAPEUTIC HOSE MEDICINE | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| EA202091653A1 (en) | MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES | |
| AR103636A1 (en) | METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND | |
| AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
| EA202091446A1 (en) | METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | |
| BR112018002433A2 (en) | pharmaceutical composition for migraine treatment | |
| EA201592261A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING AGOMELATIN IN THE FORM OF HOMELATIN CRYSTALS WITH ORGANIC ACID | |
| MX2018013474A (en) | Carboxylic acids for early childhood application. | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| MX2016006375A (en) | A combination of dosage units for use in the treatment of pre-term labour condition. | |
| EA202000253A1 (en) | APPLICATION OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLUTION THAT CONTAINS ARGININE HYDROCHLORIDE AND LEVOCARNITIN FOR THE TREATMENT OF CORONARY HEART DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |